Encompass Health sets July 1 target for its home health, hospice spinoff

Updated May 27, 11:45 a.m.

Enhabit Home Health & Hospice, the upcoming spinoff from inpatient rehabilitation and home care company Encompass Health, is expected to become an official separate entity on July 1, according to a new U.S. Securities and Exchange Commission filing.

Although still subject to "various conditions," the new publicly traded entity would include Encompass' 252 home health and 99 hospice locations. The former claimed nearly $225 million in net operating revenue across 2021 while the latter brought in a net $49 million.

Once the deal is completed, Encompass investors will own stock in both companies, according to the filing.

Additionally, Encompass shared details on the anticipated makeup of Enhabit's board of directors. Five of the nine have previously served on Encompass' board, but have committed to "an orderly and gradual transition" of five new candidates over the next two years, the company said in a statement.

"This announcement is another exciting step as Enhabit embarks on our next chapter as an independent, public company," Enhabit president and CEO Barbara Jacobsmeyer, who will also be on the board, said in a statement. "We have a comprehensive transition plan in place and are confident that the board's diverse background and experience will help guide us into the future as we work to expand what's possible for patient care at home."

Inpatient rehabilitation and home care company Encompass Health announced Jan. 19 new plans to spin off its home health and hospice business into an independent, publicly traded company.

The move is expected to become official sometime within the first half of 2022, pending regulatory approvals and other conditions, according to the announcement.

The new entity will begin rebranding the segment as Enhabit Home Health & Hospice beginning in mid-April, a process the company expects will be “largely completed” by the time the spinoff is final.

“The Encompass Health Board of Directors believes that the separation of its inpatient rehabilitation business and the [home health and hospice business] into two independent, publicly-traded companies will provide significant benefits to both businesses and their stakeholders,” Encompass wrote in its announcement.

Those benefits include “improving the strategic and operational flexibility of each business, increasing the focus of each management team on its business strategy and operations, allowing each business to adopt a capital structure and investment policy best suited to its financial profile and business needs and providing each company with its own equity currency to facilitate acquisitions and to better incentivize management,” the company wrote.

RELATED: Humana taps exec to lead its home health business

Encompass Health reported nearly $1.3 billion in net operating revenue during its most recent quarter. Its home health and hospice segment was responsible for about $274 million of that revenue (down 0.2% year over year), while inpatient rehabilitation made up the lion’s share with just over $1 billion for the third quarter (up 12.4% year over year).

The decision to split the businesses didn’t come out of left field. During the third quarter’s earnings call, President, CEO and Director Mark Tarr told investors to expect a spinoff, split-off or carve-out IPO during the first half of 2022.

“We have thoroughly evaluated a broad array of public and private transaction alternatives and further believe that affecting the separation via the formation of an independent public company is superior to the other alternatives considered,” he said at the time.

Encompass Health currently consists of 145 inpatient rehabilitation hospitals, 251 home health locations and 96 hospice locations spread across 42 states and Puerto Rico.

The company said its spinoff should be tax-free for its shareholders, who will hold stock in both companies at the end of the day.

The broader home health space saw a shakeup last year when Humana completed its $5.7 billion buyout of Kindred at Home, a purchase that made the insurer the nation’s largest provider of home healthcare services. Centene, meanwhile, announced in November that it would be selling off its majority stake in home health company U.S. Medical Management.